BRPI0511445A - métodos para distinguir uma estrutura benigna de tecido maligno, para monitorar eficiência do tratamento de cáncer, e para distinguir sub-regiões morfológicas e funcionais de região de tecido selecionado, composição e uso de análogo de éter fosfolipìdico - Google Patents
métodos para distinguir uma estrutura benigna de tecido maligno, para monitorar eficiência do tratamento de cáncer, e para distinguir sub-regiões morfológicas e funcionais de região de tecido selecionado, composição e uso de análogo de éter fosfolipìdicoInfo
- Publication number
- BRPI0511445A BRPI0511445A BRPI0511445-4A BRPI0511445A BRPI0511445A BR PI0511445 A BRPI0511445 A BR PI0511445A BR PI0511445 A BRPI0511445 A BR PI0511445A BR PI0511445 A BRPI0511445 A BR PI0511445A
- Authority
- BR
- Brazil
- Prior art keywords
- distinguishing
- methods
- morphological
- cancer treatment
- functional
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000877 morphologic effect Effects 0.000 title abstract 3
- -1 phospholipid ether analog Chemical class 0.000 title abstract 3
- 230000003211 malignant effect Effects 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000004744 fabric Substances 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002609 virtual colonoscopy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0408—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/508—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for non-human patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oral & Maxillofacial Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Dentistry (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
MéTODOS PARA DISTINGUIR UMA ESTRUTURA BENIGNA DE TECIDO MALIGNO, PARA MONITORAR EFICIêNCIA DO TRATAMENTO DE CáNCER, E PARA DISTINGUIR SUB-REGIõES MORFOLóGICAS E FUNCIONAIS DE REGIãO DE TECIDO SELECIONADO, COMPOSIçãO E USO DE ANáLOGO DE éTER FOSFOLIPìDICO. A presente invenção refere-se à disposição agentes e métodos para colonoscopia virtual de modalidade dual, que dá informações tanto anatómicas como funcionais usando exploração híbrida por CT/PET. Em modalidades preferidas, a presente invenção põe á disposição agentes específicos para tumores radiomarcados e métodos para distinguir pólipos benignos de tumores malignos. Em outras modalidades, a presente invenção põe à disposição composições e métodos úteis pra distinguir sub-regiões morfológicas e funcionais de uma região de tecido selecionada, com base em níveis relativos de metabolismo de fosfolipídios. Agentes específicos para tumores radiomarcados preferidos são análogos de éter fosfolipídico marcados com radioisótopos de halogênio. Em determinadas modalidades, as composições que incluem análogos de éter fosfolipídico radiomarcados têm ações terapêuticas, em adição a funcionalmente identificar tecido maligno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52183104P | 2004-07-08 | 2004-07-08 | |
| PCT/US2005/024259 WO2006014589A2 (en) | 2004-07-08 | 2005-07-08 | Virtual colonoscopy with radiolabeled phospholipid ether analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511445A true BRPI0511445A (pt) | 2007-12-26 |
Family
ID=35503411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511445-4A BRPI0511445A (pt) | 2004-07-08 | 2005-07-08 | métodos para distinguir uma estrutura benigna de tecido maligno, para monitorar eficiência do tratamento de cáncer, e para distinguir sub-regiões morfológicas e funcionais de região de tecido selecionado, composição e uso de análogo de éter fosfolipìdico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7700075B2 (pt) |
| EP (1) | EP1773408A2 (pt) |
| JP (1) | JP2008508909A (pt) |
| KR (1) | KR20070054630A (pt) |
| CN (1) | CN101001647A (pt) |
| AU (1) | AU2005269861A1 (pt) |
| BR (1) | BRPI0511445A (pt) |
| CA (1) | CA2572398A1 (pt) |
| IL (1) | IL180363A0 (pt) |
| MX (1) | MX2007000207A (pt) |
| NO (1) | NO20070705L (pt) |
| NZ (1) | NZ552914A (pt) |
| WO (1) | WO2006014589A2 (pt) |
| ZA (1) | ZA200700015B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8540968B2 (en) * | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| MXPA06009681A (es) * | 2004-03-02 | 2007-03-15 | Cellectar Llc | Analogos de fosfolipido para el diagnostico y tratamiento del cancer. |
| KR20080005178A (ko) * | 2004-12-20 | 2008-01-10 | 셀렉타, 엘엘씨 | 암 검출 및 치료용 인지질 에테르 동족체 |
| WO2006114658A2 (en) * | 2005-04-28 | 2006-11-02 | Yeda Research And Development Co., Ltd | Lung cancer diagnosis using magnetic resonance imaging data obtained at three time points |
| US7414254B2 (en) * | 2005-06-28 | 2008-08-19 | United Pharmacy Partners, Inc. | Tungsten pig for radio-pharmaceuticals |
| US20070208331A1 (en) * | 2006-03-02 | 2007-09-06 | Chu Michael S | Systems and methods of treatment within a gastrointestinal lumen |
| EP1985713A1 (en) * | 2007-04-05 | 2008-10-29 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Methods and tools for detecting the presence of colorectal adenocarcinoma cells |
| US20080319315A1 (en) * | 2007-06-07 | 2008-12-25 | Beth Israel Deaconess Medical Center | Method of reducing interferences in positron emission tomography |
| WO2010011844A1 (en) * | 2008-07-25 | 2010-01-28 | Tufts Medical Center | A system and method of clinical treatment planning of complex, monte carlo-based brachytherapy dose distributions |
| EP2429591B1 (en) | 2009-05-11 | 2015-08-26 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
| US8871181B2 (en) | 2009-05-11 | 2014-10-28 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
| WO2010144788A2 (en) * | 2009-06-12 | 2010-12-16 | Cellectar, Inc. | Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells |
| JP2013504590A (ja) * | 2009-09-11 | 2013-02-07 | セレクター，インコーポレイティド | 非放射性リン脂質化合物、組成物、及び使用方法 |
| EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
| KR101341288B1 (ko) | 2013-10-24 | 2013-12-12 | 사회복지법인 삼성생명공익재단 | 방사선 치료기의 품질 보증 시스템 및 그 품질 보증 방법 |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| DK3750545T3 (da) | 2014-11-17 | 2024-04-22 | Cellectar Biosciences Inc | Phospholipidetheranaloger som cancermålrettede lægemiddelbærere |
| JP6841609B2 (ja) | 2015-07-10 | 2021-03-10 | ３スキャン インコーポレイテッド | 組織学的染色の空間的多重化 |
| AU2017300361A1 (en) * | 2016-07-18 | 2019-02-07 | Wisconsin Alumni Research Foundation | Radiohalogenated agents for In Situ Immune Modulated Cancer Vaccination |
| RU2755010C1 (ru) * | 2021-01-26 | 2021-09-09 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Способ диагностики рака ободочной кишки |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925649A (en) | 1987-06-12 | 1990-05-15 | The University Of Michigan | Radioiodinated diacylglycerol analogues and methods of use |
| US5347030A (en) | 1987-10-23 | 1994-09-13 | The Board Of Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogues and methods of using same |
| US5087721A (en) | 1987-10-23 | 1992-02-11 | The University Of Michigan | Radioiodinated phosphate esters |
| US4965391A (en) | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
| US5369097A (en) | 1991-04-25 | 1994-11-29 | The University Of British Columbia | Phosphonates as anti-cancer agents |
| US6255519B1 (en) * | 1996-12-04 | 2001-07-03 | Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
| MXPA06009681A (es) * | 2004-03-02 | 2007-03-15 | Cellectar Llc | Analogos de fosfolipido para el diagnostico y tratamiento del cancer. |
| KR20080005178A (ko) * | 2004-12-20 | 2008-01-10 | 셀렉타, 엘엘씨 | 암 검출 및 치료용 인지질 에테르 동족체 |
| CN100415584C (zh) * | 2005-02-04 | 2008-09-03 | 比亚迪股份有限公司 | 机动车制动防抱死的控制系统和方法 |
-
2005
- 2005-07-08 CA CA002572398A patent/CA2572398A1/en not_active Abandoned
- 2005-07-08 KR KR1020077003022A patent/KR20070054630A/ko not_active Application Discontinuation
- 2005-07-08 US US11/177,749 patent/US7700075B2/en active Active
- 2005-07-08 BR BRPI0511445-4A patent/BRPI0511445A/pt not_active IP Right Cessation
- 2005-07-08 JP JP2007520532A patent/JP2008508909A/ja active Pending
- 2005-07-08 AU AU2005269861A patent/AU2005269861A1/en not_active Abandoned
- 2005-07-08 WO PCT/US2005/024259 patent/WO2006014589A2/en active Application Filing
- 2005-07-08 CN CNA2005800269356A patent/CN101001647A/zh active Pending
- 2005-07-08 MX MX2007000207A patent/MX2007000207A/es not_active Application Discontinuation
- 2005-07-08 EP EP05769481A patent/EP1773408A2/en not_active Withdrawn
- 2005-07-08 NZ NZ552914A patent/NZ552914A/en unknown
-
2006
- 2006-12-26 IL IL180363A patent/IL180363A0/en unknown
-
2007
- 2007-01-02 ZA ZA200700015A patent/ZA200700015B/xx unknown
- 2007-02-07 NO NO20070705A patent/NO20070705L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005269861A2 (en) | 2006-02-09 |
| US7700075B2 (en) | 2010-04-20 |
| US20070098633A2 (en) | 2007-05-03 |
| WO2006014589A2 (en) | 2006-02-09 |
| JP2008508909A (ja) | 2008-03-27 |
| MX2007000207A (es) | 2007-03-30 |
| CA2572398A1 (en) | 2006-02-09 |
| IL180363A0 (en) | 2007-06-03 |
| US20060013767A1 (en) | 2006-01-19 |
| WO2006014589A3 (en) | 2006-04-20 |
| ZA200700015B (en) | 2008-09-25 |
| NO20070705L (no) | 2007-04-02 |
| KR20070054630A (ko) | 2007-05-29 |
| NZ552914A (en) | 2009-12-24 |
| CN101001647A (zh) | 2007-07-18 |
| EP1773408A2 (en) | 2007-04-18 |
| AU2005269861A1 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511445A (pt) | métodos para distinguir uma estrutura benigna de tecido maligno, para monitorar eficiência do tratamento de cáncer, e para distinguir sub-regiões morfológicas e funcionais de região de tecido selecionado, composição e uso de análogo de éter fosfolipìdico | |
| Benešová et al. | Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer | |
| Van Nostrand | The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer | |
| Bhushan et al. | Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe | |
| Fuccio et al. | Androgen deprivation therapy influences the uptake of 11 C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study | |
| SI1472541T1 (sl) | Prikazovalni agensi in postopek prikazovanja naaladase ali psma | |
| Buchegger et al. | First imaging results of an intraindividual comparison of 11 C-acetate and 18 F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy | |
| BR0110091A (pt) | Composições e processos para terapia e diagnóstico de câncer de mama | |
| Duet et al. | Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia | |
| BR0009537A (pt) | Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso | |
| UY32037A (es) | Daa-piridina | |
| BR0012069A (pt) | Composições e métodos para a terapia e diagnóstico de câncer pulmonar | |
| BR9912007A (pt) | Composições e métodos para terapia e diagnóstico de câncer de próstata | |
| DE602005025211D1 (de) | Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen | |
| BRPI0507684A (pt) | agentes de contraste para formação de imagem de perfusão miocárdica | |
| NZ606466A (en) | Peptide radiotracer compositions | |
| Dong et al. | SPECT/NIRF dual modality imaging for detection of intraperitoneal colon tumor with an avidin/biotin pretargeting system | |
| Rasaneh et al. | Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines | |
| Tolmachev et al. | Molecular design of radiocopper-labelled Affibody molecules | |
| Wolden et al. | Sarcomas across the age spectrum | |
| Papaxoinis et al. | Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG) | |
| BRPI0417187A (pt) | métodos e kits relacionados à administração de um frutooligossacarìdeo | |
| NZ591824A (en) | Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system | |
| Sinzinger et al. | Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP | |
| BR0012446A (pt) | Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |